| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
177,680,000 |
| Market
Cap: |
8.08(B) |
| Last
Volume: |
2,144,916 |
Avg
Vol: |
1,949,015 |
| 52
Week Range: |
$44.82 - $99.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : 568 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile Exact Sciences is a cancer screening and diagnostics company. Co.'s primary screening product, the Cologuard® test, is a non-invasive stool-based DNA screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. Co.'s portfolio of Oncotype tests include: Oncotype DX gene expression tests for breast, prostate and colon cancers; Oncotype DX AR-V7 Nucleus Detect® test, a liquid-based test for advanced stage prostate cancer; and Oncotype MAP™ Pan-Cancer Tissue test (oncomap test), a test delivering tumor profiling to aid therapy selection for patients with metastatic, refractory or recurrent cancer.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
6,762 |
108,398 |
166,494 |
290,334 |
| Total Sell Value |
$463,948 |
$6,570,910 |
$11,277,891 |
$18,676,003 |
| Total People Sold |
8 |
10 |
11 |
11 |
| Total Sell Transactions |
11 |
52 |
61 |
100 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Arora Maneesh |
COO |
• • – |
2018-02-26 |
4 |
AS |
$42.34 |
$522,959 |
D/D |
(12,352) |
632,471 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-02-26 |
4 |
AS |
$42.34 |
$303,902 |
D/D |
(7,178) |
206,596 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-02-26 |
4 |
AS |
$42.34 |
$187,134 |
D/D |
(4,420) |
49,010 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2018-02-26 |
4 |
AS |
$42.34 |
$126,252 |
D/D |
(2,982) |
21,012 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-02-26 |
4 |
AS |
$42.34 |
$1,071,956 |
D/D |
(25,319) |
858,558 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2018-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,000 |
644,823 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
8,250 |
213,774 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-02-24 |
4 |
OE |
$0.00 |
$0 |
D/D |
19,500 |
883,877 |
|
- |
|
| Arora Maneesh |
COO |
• • – |
2018-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
18,875 |
633,823 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-02-23 |
4 |
AS |
$39.60 |
$805,364 |
D/D |
(20,250) |
205,524 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2018-02-23 |
4 |
OE |
$0.00 |
$439,020 |
D/D |
31,825 |
225,774 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
12,850 |
53,430 |
|
- |
|
| Elliott Jeffrey Thomas |
Chief Financial Officer |
• – – |
2018-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,300 |
23,994 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-02-23 |
4 |
OE |
$0.00 |
$0 |
D/D |
34,325 |
864,377 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-02-09 |
4 |
AS |
$44.60 |
$4,640,272 |
D/D |
(101,488) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-02-09 |
4 |
OE |
$0.83 |
$84,235 |
D/D |
101,488 |
931,540 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-01-23 |
4 |
AS |
$48.87 |
$5,575,961 |
D/D |
(110,439) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-01-23 |
4 |
OE |
$0.83 |
$91,664 |
D/D |
110,439 |
940,491 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-01-12 |
4 |
AS |
$52.68 |
$6,620,593 |
D/D |
(125,402) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2018-01-12 |
4 |
OE |
$0.83 |
$104,084 |
D/D |
125,402 |
955,454 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-01-03 |
4 |
AS |
$52.54 |
$87,474 |
D/D |
(1,665) |
40,580 |
|
- |
|
| Coward D Scott |
SVP and General Counsel |
• – – |
2018-01-02 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,687 |
42,245 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-12-06 |
4 |
AS |
$53.35 |
$6,513,179 |
D/D |
(121,849) |
830,052 |
|
- |
|
| Conroy Kevin T |
President and CEO |
• • – |
2017-12-06 |
4 |
OE |
$0.83 |
$101,135 |
D/D |
121,849 |
951,901 |
|
- |
|
| Lidgard Graham Peter |
Chief Science Officer |
• – – |
2017-12-01 |
4 |
AS |
$57.05 |
$2,667,204 |
D/D |
(45,770) |
193,949 |
|
- |
|
777 Records found
|
|
Page 22 of 32 |
|
|
0.20 (0.44%) 
